Figure 6

Treatment with 4-PBA alleviated lipid metabolic disorders in SCH mice.

(A) Levels of triglycerides (TG), total cholesterol (TC), high-density lipoprotein (HDL) and low-density lipoprotein (LDL) in the serum of all mice were determined after 4-PBA was administered for 4 weeks (n = 6–12). (B) Hepatic TC contents were detected using a cholesterol assay kit after 4-PBA was administered for 4 weeks (n = 6–12). (C) Hepatic TG contents were detected using a triglyceride assay kit after 4-PBA was administered for 4 weeks (n = 6–13). (D) Filipin staining was used to measure hepatic cholesterol deposition after 4-PBA was administered for 4 weeks (n = 3). Original magnification: 200×. (E) Oil red O staining was used to measure hepatic TG accumulation after 4-PBA was administered for 4 weeks (n = 3). Original magnification: 200×. (F) Real-time PCR analysis of different lipid metabolism-related genes in the liver was performed in the 18th week (n = 4–6). The data are presented as the mean ± SD. *p < 0.05 compared with the vehicle-treated group. ^#p < 0.05 compared with the 4-PBA-treated SCH group. The results are representative of 3 independent experiments.